Pembrolizumab vs Tofacitinib

## Pembrolizumab vs Tofacitinib: Overview

This comparison examines the pharmacological differences between **Pembrolizumab** and **Tofacitinib**.

## Mechanism of Action

**Pembrolizumab**: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

**Tofacitinib**: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

## Pharmacokinetics

**Half-life**: Pembrolizumab — 26 days; Tofacitinib — 3.2 hours.

## Chemical Properties

**Molecular Formula**: Pembrolizumab — N/A; Tofacitinib — C16H20N6O.

**Molecular Weight**: Pembrolizumab — N/A; Tofacitinib — 312.3700 g/mol.

**Type**: Pembrolizumab — Antibody; Tofacitinib — Small molecule.